MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. While pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management.

Source link

Related posts

Cardiorespiratory Fitness Tied to Lower Risk for Lung Cancer, CRC


Ghrelin is impacted by the endogenous circadian system and by circadian misalignment in humans


ACG President announces telehealth initiative, lauds concrete accomplishments


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy